The above study may pertain to certain members of this wonderful forum. I am not a medical professional so please don't rely on anything that I am writing but go to the article above. Dr. Ueno also answers questions.
with my love to all here,
Steve
I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates
Thanks for posting this very interesting study showing a high percentage (56%) of sub-type change after neoadjuvant chemo without a pathological complete response.
PURPOSE
Lehmann
et al have identified four molecular subtypes of triple-negative breast
cancer (TNBC)—basal-like (BL) 1, BL2, mesenchymal (M), and luminal
androgen receptor—and an immunomodulatory (IM) gene expression signature
modifier. Our group previously showed that the response of TNBC to
neoadjuvant systemic chemotherapy (NST) differs by molecular subtype,
but whether NST affects the subtype was unknown. Here, we tested the
hypothesis that in patients without pathologic complete response, TNBC
subtypes can change after NST. Moreover, in cases with the changed
subtype, we determined whether epithelial-to-mesenchymal transition
(EMT) had occurred.
MATERIALS AND METHODS
From
the Pan-Pacific TNBC Consortium data set containing TNBC patient
samples from four countries, we examined 64 formalin-fixed,
paraffin-embedded pairs of matched pre- and post-NST tumor samples. The
TNBC subtype was determined using the TNBCtype-IM assay. We analyzed a
partial EMT gene expression scoring metric using mRNA data.
RESULTS
Of
the 64 matched pairs, 36 (56%) showed a change in the TNBC subtype
after NST. The most frequent change was from BL1 to M subtypes (38%). No
tumors changed from M to BL1. The IM signature was positive in 14 (22%)
patients before NST and eight (12.5%) patients after NST. The EMT score
increased after NST in 28 (78%) of the 36 patients with the changed
subtype (v 39% of the 28 patients without change; P = .002254).
CONCLUSION
We
report, to our knowledge, for the first time that the TNBC molecular
subtype and IM signature frequently change after NST. Our results also
suggest that EMT is promoted by NST. Our findings may lead to innovative
adjuvant therapy strategies in TNBC cases with residual tumor after
NST.
Edited by 123Donna - Jul 15 2022 at 7:24pm
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
I don't think it is that simple because many people on this forum have had lumpectomies but have not had neo-adjuvant chemotherapy, or even at times, rarely, no chemotherapy post lumpectomy.
So, in the case you are mentioning the chemotherapy would have had to be completed prior to the lumpectomy for it to be defined as a pCR. It sounds like you had a lumpectomy and then chemo?
Hope the above helps. Also, there are women who have neoadjuvant chemo and then bi-lateral mastectomies (like my daughter) who did not have lymph node involvement and were advised that they did not need radiation therapy. The bi-lateral mastectomies were eventually advised due to her having the BRCA mutation. Unfortunately, her breast surgical oncologist did not have her tested for the BRCA mutation in 2004. That still happens today but, fortunately, no genetic testing happens much less frequently.
warmly,
Steve
I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates
I think one of the few things that I have learned for sure in the last 18 years helping my daughter and then many on this site with TNBC is that oncologists can craft protocols and not know with any precision whether they will work or not.
I rejoice in your information, below, that you have just passed your 5 year mark passed your RADS and I don't see any other issues, which unfortunately is not the case, all too often, with others on this forum.
I tell everyone I help to "please try to find the beauty in each day" and be grateful for that beauty. My daughter is now NED for 18 years and we are both grateful she is and I am grateful to see no further incidents after 2017 in your history.
Could you have gotten by with less treatment? Maybe? But what you did, seems to have worked, and for others here with less or more treatment it has not for whatever reason. So, I rejoice for you that you seem to be NED, the nicest acronym in the English language to me, No Evidence of Disease. May it always continue for you, my daughter and for so many here.
And for those of you still fighting the fight, my heart is with you and I wish you success and hope you can find the beauty in each day, as often as possible.
with my love to all here,
Steve
I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum